These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37856201)

  • 1. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
    Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
    J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
    Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
    J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
    Kwong A; Chen JW; Shin VY
    Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What attitude to women at high risk of breast cancer?].
    Livon D; Moretta J; Noguès C
    Presse Med; 2019 Oct; 48(10):1092-1100. PubMed ID: 31706893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
    Daly MB; Pilarski R; Axilbund JE; Buys SS; Crawford B; Friedman S; Garber JE; Horton C; Kaklamani V; Klein C; Kohlmann W; Kurian A; Litton J; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Pasche B; Reiser G; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wiesner GL; Dwyer MA; Kumar R;
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1326-38. PubMed ID: 25190698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Sorscher S; Ansley K; Delaney SD; Ramkissoon S
    Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
    Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
    Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.